Infliximab does not activate replication of lymphotropic herpesviruses in patients with refractory rheumatoid arthritis

Rheumatology

Volumn 44, Issue 9, 2005, Pages 1132-1135

  Torre Cisneros, Julian ^a   del Castillo, M ^b   Caston J J ^a   Castro, M C ^a   Perez V ^a   Collantes, E ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b Hospital Punta Europa   (Spain)

Author keywords

CMV; Herpesviruses; Infliximab; Latent infection; Rheumatoid arthritis

Indexed keywords

DICLOFENAC; INDOMETACIN; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VIRUS DNA;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DNA DETERMINATION; DOSE RESPONSE; DRUG INDICATION; EPSTEIN BARR VIRUS; FEMALE; HERPES VIRUS INFECTION; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 6; IMMUNOSUPPRESSIVE TREATMENT; LATENT VIRUS INFECTION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RHEUMATOID ARTHRITIS; VIRUS INFECTION; VIRUS LOAD; VIRUS REACTIVATION; VIRUS REPLICATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; DNA, VIRAL; FEMALE; HERPESVIRIDAE; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA; VIRUS ACTIVATION;

EID: 24144477565     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keh696     Document Type: Article

References (15)

1. Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-a therapy. Rheumatology 2003;42:617-21.
2. Mikuls TR, Moreland LW. Benefit-risk assessment of infliximab in the treatment of rheumatoid arthritis. Drug Safety 2003;26:23-32.
3. Long R, Gardam M. Tumour necrosis factor-α inhibitors and the reactivation of latent tuberculosis infection. Can Med Assoc J 2003;168:1153-6.
4. Cunnane G, Doran M, Bresnihan B. Infections and biological therapy in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2003;17:345-63.
5. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor a-neutralizing agent. N Engl J Med 2001;345:1098-104.
6. Gómez-Reino JJ, Carmona L, Rodríguez Valverde V, Martín Mola E, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003;48:2122-7.
7. US Food and Drug Administration. Safety update on TNF-α antagonists: infliximab and etanercept. Washington, DC: US Food and Drug Administration, 2002.
8. Lee JH, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel JN. Life-threatening histoplasmosis complicating immunotherapy with tumour necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002;46:2565-70.
9. Caserta M, Mock D, Dewhurst S. Human herpesvirus 6. Clin Infect Dis 2001;33:829-33.
10. Humar A, Malkan G, Moussa G, Greig P, Levy G, Mazzulli T. Human herpesvirus-6 is associated with cytomegalovirus reactivation in liver transplant recipients. J Infect Dis 2000;181: 1450-3.
11. Okuno T, Higashi K, Shiraki K, Yamaniski K, Takahashi M, Kokado Y. Human herpesvirus 6 infection in renal transplantation. Transplantation 1990;49:519-22.
12. Pozo F, Tenorio A. Detection and typing of human herpesviruses by multiplex polymerase chain reaction. J Virol Methods 1999; 72:8143-9.
13. Mendez JC, Dockrell DH, Espy MJ et al. Human β-herpesvirus interactions in solid organ transplant recipients. J Infect Dis 2001;183:179-84.
14. Ratnamohan VM, Chapman J, Howse H, Bovington K, Robertson P, Byth K. Cytomegalovirus and human herpesvirus 6 both cause viral disease after renal transplantation. Transplantation 1998;66:877-82.
15. Torre-Cisneros J, Pozo F, Serrano R, Vidal E, Rivero A, Tenorio A. Patterns of lymphotropic herpesvirus viraemia in HIV-infected patients with Kaposi's sarcoma treated with highly active antiretroviral therapy and liposomal daunorrubicin. AIDS 2000;14:2215-7.